News Wire ~ 3rd Party Press Release

197 POSTS 0 COMMENTS
Alladapt

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy...

Company is developing therapy to target a number of food allergies simultaneously.
EAT Grand Challenge

End Allergies Together Announces Winners of $1 Million Grand Challenge to End Anaphylaxis

New microbiome treatments and targets win Challenge as decided by distinguished panel of scientists, investors and entrepreneurs.
Tablets

Study: Co-Treatments Like Antihistamines and Probiotics Make Peanut OIT Success in Children More Likely

“These findings suggest that slight modifications to treatment protocols could play a key role in substantially improving treatment safety.”
Aimmune + Xencor

Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food...

“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
AAAAI Palforzia Release

What You Need to Know About the First Peanut Allergy Treatment Approved by the...

Information for patients and their families about this new treatment option, what it means, and why it won’t be right for everyone.
Palforzia

FDA Approves Aimmune’s PALFORZIA as First Treatment for Peanut Allergy

Palforzia is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
FARE Website

FARE Launches Enhanced Website

Site features a streamlined design, enhanced search functions, and simplified access to key food allergy resources and information
Peanut Allergy Vaccine

Allergy Therapeutics Publishes Encouraging New Data for Peanut Allergy Vaccine Candidate

"This study indicates a paradigm shift by addressing peanut allergy via a vaccination concept instead of classic desensitisation..."
Vitapul Team

Team Developing Novel Auto-Injector Wins Grand Prize at Opportunity Quest Competition

Device promises better thermal stability and longer shelf life.